Support Alert

Medicine Supply Notification - Lorazepam (Ativan) 4mg/ml injection (tier 2), Penicillamine 125mg and 250mg tablets (tier 2) and an update on resupply dates

The Department of Health and Social Care (DHSC) has issued two Medicine Supply Notifications. 


Pfizer have limited supplies of lorazepam 4mg/ml injection so will be restricting orders direct to pharmacies in line with 50% historical demand between now and w/c 2nd March. Further information, including actions required is available in the DHSC Medicine Supply Notification.


Penicillamine 125mg is out of stock. Limited supplies of penicillamine 250mg tablets are available through hospital pharmacies only. Further information, including actions required is available in the DHSC Medicine Supply Notification.
 

Please find an update below for changes to the resupply dates of certain medicines. 

Original MSN reference

Date of original Medicine Supply Notification (MSN)

Supply issue

Resupply date previously communicated

Updated resupply date as of

February 2020

MSN/2019/020

20-Dec-19

H2-antagonists (cimetidine, famotidine and nizatidine)

Famotidine 20mg tablets are out of stock until the end of December 2019.

 

Cimetidine 200mg tablets are out of stock until the end of January 2020.

 

Nizatidine 150mg and 300mg tablets are out of stock until February 2020.

End February 2020 (Tillomed)

Mid March 2020 (Teva)

 

End March 2020 (Ennogen)

May 2020 (Medley Pharma)

 

No confirmed resupply date (Medreich and Mylan)

MSN/2020/005

11-Feb-20

Salbutamol  2mg/5ml syrup

End of February 2020

End of March 2020

n/a

23-Aug-19

Sayana Press Injection

At least end 2019

March 2020

n/a

24-Oct-19

Paroxetine (Seroxat) 10mg/5ml liquid

January 2020

Early March 2020

MSN/2019/003

01-Nov-19

Mesalazine (Salofalk) 1g suppositories

20 December 2019

Mid-September 2020

Loading...

Email newsletter

Want the latest pharmacy news and updates straight to your inbox?

Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.

Sign Up